CDX2
CDX2 (Homeobox protein CDX-2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Oesophageal cancer, Skin cancer and 3 more.
Overview
Transcription factor which regulates the transcription of multiple genes expressed in the intestinal epithelium. Binds to the promoter of the intestinal sucrase-isomaltase SI and activates SI transcription. Binds to the DNA sequence 5'-ATAAAAACTTAT-3' in the promoter region of VDR and activates VDR transcription.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant. Open Targets scores its association with cancer at 0.66 (direct and indirect evidence; datatypes literature 0.99, affected pathway 0.33, animal model 0.66, somatic mutation 0.81). IntOGen calls it a driver in 1 cohort (0 activating, 1 loss-of-function), covering Oesophageal Adenocarcinoma.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · CDX2 (Homeobox protein CDX-2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Oesophageal cancer, Skin cancer and 3 more.
- 1 · What it is
CDX2 (Homeobox protein CDX-2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Oesophageal cancer, Skin cancer and 3 more.
- 2 · What goes wrong in cancer
Transcription factor which regulates the transcription of multiple genes expressed in the intestinal epithelium. Binds to the promoter of the intestinal sucrase-isomaltase SI and activates SI transcription.
- 3 · How drugs use it
No product in this corpus aims at CDX2 yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
External identifiers
Sources: HGNC HGNC:1806 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q99626 (protein name, function text, keywords and locations (REST API)); CIViC gene CDX2 (1 evidence items, 0 assertions, 1 variants; diseases: Colorectal Cancer (GraphQL API, CC0)); Open Targets ENSG00000165556 (association with cancer (MONDO_0004992) 0.66; per-cancer scores at or above 0.5: melanoma 0.53, skin cancer 0.53, lung cancer 0.51 (GraphQL API, CC0)); IntOGen CDX2 (driver in 1 cohort (Act 0, LoF 1); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Transcription factor which regulates the transcription of multiple genes expressed in the intestinal epithelium. Binds to the promoter of the intestinal sucrase-isomaltase SI and activates SI transcription. Binds to the DNA sequence 5'-ATAAAAACTTAT-3' in the promoter region of VDR and activates VDR transcription. Binds to and activates transcription of LPH. Activates transcription of CLDN2 and intestinal mucin MUC2. Binds to the 5'-AATTTTTTACAACACCT-3' DNA sequence in the promoter region of CA1 and activates CA1 transcription. Location: Nucleus (UniProt). Locus 13q12.2 (HGNC).
- Colorectal cancer: CIViC evidence names this disease
- Oesophageal cancer: IntOGen driver in 1 cohort (ESCA)
- Skin cancer: Open Targets association 0.53 with skin cancer (MONDO_0002898)
- Lung cancer: Open Targets association 0.51 with lung cancer (MONDO_0008903)
- Oesophageal and junctional adenocarcinoma: IntOGen driver in 1 cohort (ESCA)
- Melanoma: Open Targets association 0.53 with melanoma (MONDO_0005105)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it a loss-of-function (LoF) driver in 1 cohort; CIViC holds 1 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"CDX2" OR ABSTRACT:"CDX2" OR TITLE:"caudal type homeobox 2" OR ABSTRACT:"caudal type homeobox 2" OR TITLE:"Homeobox protein CDX-2" OR ABSTRACT:"Homeobox protein CDX-2" OR TITLE:"CDX3" OR ABSTRACT:"CDX3") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CDX2, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetKAT6A
Shares Oesophageal and junctional adenocarcinoma, Lung cancer (all types), Skin cancer (all types), Oesophageal cancer.
- TargetNUTM1
Shares Oesophageal and junctional adenocarcinoma, Lung cancer (all types), Skin cancer (all types), Oesophageal cancer.
- TargetAFDN
Shares Lung cancer (all types), Skin cancer (all types), IntOGen, Melanoma.
- TargetATP2B3
Shares Lung cancer (all types), Skin cancer (all types), IntOGen, Melanoma.
- TargetCIITA
Shares Lung cancer (all types), Skin cancer (all types), CIViC, IntOGen.
- TargetSMAD3
Shares Lung cancer (all types), Skin cancer (all types), CIViC, IntOGen.
- TargetCBLB
Shares Lung cancer (all types), Skin cancer (all types), CIViC, IntOGen.
- TargetCRLF2
Shares Lung cancer (all types), Skin cancer (all types), CIViC, IntOGen.